logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Kazuhiko Shibata

Ishikawa Prefectural Central Hospital
H指数:16
被引数:5,598

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

帕博利珠单抗作为非小细胞肺癌患者（PD-L1肿瘤比例评分≥50%）一线治疗的五年疗效和安全性：一项多中心观察性研究

LUNG CANCER
IF4.4
2025-03-011
PRE
Tambo, Yuichi; Sone, Takashi; Nishi, Koichi; Shibata, Kazuhiko; Kita, Toshiyuki; Araya, Tomoyuki; Shirasaki, Hiroki; Shimizu, Takahiro; Yoneda, Taro; Matsuoka, Hiroki; Nanjo, Shigeki; Koba, Hayato; Terada, Nanao; Ueda, Tsukasa; Nomura, Shunichi; Murase, Yuya; Yano, Seiji
EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer
TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2024-11-010
OAAI
Terada, Nanao; Koba, Hayato; Nanjo, Shigeki; Kimura, Hideharu; Nishiyama, Akihiro; Yoneda, Taro; Takeda, Takayuki; Shirasaki, Hiroki; Nishi, Koichi; Sone, Takashi; Yamada, Tadaaki; Takayama, Koichi; Shibata, Kazuhiko; Matsuoka, Hiroki; Kita, Toshiyuki; Nagata, Kazuhiro; Tambo, Yuichi; Ohkura, Noriyuki; Hara, Johsuke; Kasahara, Kazuo; Kohsaka, Shinji; Mano, Hiroyuki; Yano, Seiji
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2022-12-183
OAAI
Tanaka, Hisashi; Tanzawa, Shigeru; Misumi, Toshihiro; Makiguchi, Tomonori; Inaba, Megumi; Honda, Takeshi; Nakamura, Junya; Inoue, Koji; Kishikawa, Takayuki; Nakashima, Masanao; Fujiwara, Keiichi; Kohyama, Tadashi; Ishida, Hiroo; Kuyama, Shoichi; Miyazawa, Naoki; Nakamura, Tomomi; Miyawaki, Hiroshi; Oda, Naohiro; Ishikawa, Nobuhisa; Morinaga, Ryotaro; Kusaka, Kei; Fujimoto, Nobukazu; Fukuda, Yasushi; Yasugi, Masayuki; Tsuda, Takeshi; Ushijima, Sunao; Shibata, Kazuhiko; Shibayama, Takuo; Bessho, Akihiro; Kaira, Kyoichi; Shiraishi, Kenshiro; Matsutani, Noriyuki; Seki, Nobuhiko
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

使用日本上市后所有病例监测数据对Pembrolizumab单药治疗NSCLC的真实数据分析

JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2022-11-013
OA
Terai, Hideki; Soejima, Kenzo; Shimokawa, Asanao; Horinouchi, Hidehito; Shimizu, Junichi; Hase, Tetsunari; Kanemaru, Ryota; Watanabe, Kana; Ninomiya, Kiichiro; Aragane, Naoko; Yanagitani, Noriko; Sakata, Yoshihiko; Seike, Masahiro; Fujimoto, Daichi; Kasajima, Masashi; Kubo, Akihito; Kusumoto, Sojiro; Oyamada, Yoshitaka; Fujiwara, Keiichi; Mori, Masahide; Hashimoto, Midori; Shingyoji, Masato; Kodani, Masahiro; Sakamoto, Jin; Agatsuma, Toshihiko; Kashiwabara, Kosuke; Inomata, Minehiko; Tachihara, Motoko; Tanaka, Kazuhisa; Hayashihara, Kenji; Koyama, Nobuyuki; Matsui, Kaoru; Minato, Koichi; Jingu, Daisuke; Sakashita, Hiroyuki; Hara, Satoshi; Naito, Tomoyuki; Okada, Asuka; Tanahashi, Masayuki; Sato, Yuki; Asano, Koichiro; Takeda, Takayuki; Nakazawa, Kensuke; Harada, Toshiyuki; Shibata, Kazuhiko; Kato, Tatsuo; Miyaoka, Etsuo; Yoshino, Ichiro; Gemma, Akihiko; Mitsudomi, Tetsuya
Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings

在现实环境中使用免疫检查点抑制剂单药治疗的非小细胞肺癌患者的长期生存

CLINICAL LUNG CANCER
IF3.3
2022-09-0115
PRE
Yoneda, Taro; Sone, Takashi; Koba, Hayato; Shibata, Kazuhiko; Suzuki, Junya; Tani, Mayuko; Nishitsuji, Masaru; Nishi, Koichi; Kobayashi, Takafumi; Shirasaki, Hiroki; Araya, Tomoyuki; Kita, Toshiyuki; Kase, Kazumasa; Yamamura, Kenta; Terada, Nanao; Nishikawa, Shingo; Tambo, Yuichi; Kimura, Hideharu; Kasahara, Kazuo
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2022-07-291
OAAI
Tanzawa, Shigeru; Makiguchi, Tomonori; Tasaka, Sadatomo; Inaba, Megumi; Ochiai, Ryosuke; Nakamura, Junya; Inoue, Koji; Kishikawa, Takayuki; Nakashima, Masanao; Fujiwara, Keiichi; Kohyama, Tadashi; Ishida, Hiroo; Kuyama, Shoichi; Miyazawa, Naoki; Nakamura, Tomomi; Miyawaki, Hiroshi; Oda, Naohiro; Ishikawa, Nobuhisa; Morinaga, Ryotaro; Kusaka, Kei; Miyamoto, Yosuke; Yokoyama, Toshihide; Matsumoto, Chiaki; Tsuda, Takeshi; Ushijima, Sunao; Shibata, Kazuhiko; Shibayama, Takuo; Bessho, Akihiro; Kaira, Kyoichi; Misumi, Toshihiro; Shiraishi, Kenshiro; Matsutani, Noriyuki; Seki, Nobuhiko
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2021-02-272
OAAI
Tanzawa, Shigeru; Ushijima, Sunao; Shibata, Kazuhiko; Shibayama, Takuo; Bessho, Akihiro; Kaira, Kyoichi; Misumi, Toshihiro; Shiraishi, Kenshiro; Matsutani, Noriyuki; Tanaka, Hisashi; Inaba, Megumi; Haruyama, Terunobu; Nakamura, Junya; Kishikawa, Takayuki; Nakashima, Masanao; Iwasa, Keiichi; Fujiwara, Keiichi; Kohyama, Tadashi; Kuyama, Shoichi; Miyazawa, Naoki; Nakamura, Tomomi; Miyawaki, Hiroshi; Ishida, Hiroo; Oda, Naohiro; Ishikawa, Nobuhisa; Morinaga, Ryotaro; Kusaka, Kei; Fujimoto, Nobukazu; Yokoyama, Toshihide; Gemba, Kenichi; Tsuda, Takeshi; Nakagawa, Hideyuki; Ono, Hirotaka; Shimizu, Tetsuo; Nakamura, Morio; Kusumoto, Sojiro; Hayashi, Ryuji; Shirasaki, Hiroki; Ochi, Nobuaki; Aoe, Keisuke; Kanaji, Nobuhiro; Kashiwabara, Kosuke; Inoue, Hiroshi; Seki, Nobuhiko
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

WJTOG3405的最终总生存期结果，一项随机III期试验，比较吉非替尼与顺铂和多西他赛作为IIIB/IV期或术后复发EGFR突变阳性非小细胞肺癌患者的一线治疗

ANNALS OF ONCOLOGY
IF65.4
2019-12-0169
OAAI
Yoshioka, H.; Shimokawa, M.; Seto, T.; Morita, S.; Yatabe, Y.; Okamoto, I; Tsurutani, J.; Satouchi, M.; Hirashima, T.; Atagi, S.; Shibata, K.; Saito, H.; Toyooka, S.; Yamamoto, N.; Nakagawa, K.; Mitsudomi, T.
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

吉非替尼治疗表皮生长因子受体突变的晚期非小细胞肺癌的多中心前瞻性II期试验: 西日本胸腔肿瘤学组试验 (WJTOG0403) 的结果

BRITISH JOURNAL OF CANCER
IF6.8
2008-02-19186
OAAI
Tamura, K.; Okamoto, I.; Kashii, T.; Negoro, S.; Hirashima, T.; Kudoh, S.; Ichinose, Y.; Ebi, N.; Shibata, K.; Nishimura, T.; Katakami, N.; Sawa, T.; Shimizu, E.; Fukuoka, J.; Satoh, T.; Fukuoka, M.

研究方向

暂未获取到该数据
K
Kazuo Kasahara
H 指数:40论文数:443被引数:9,552
H
Hiroki Shirasaki
H 指数:11论文数:51被引数:348
T
Takashi Sone
H 指数:22论文数:147被引数:1,785
T
Taro Yoneda
H 指数:10论文数:58被引数:260
K
Keiichi Fujiwara
H 指数:59论文数:662被引数:1.7万
Y
Yuichi Tambo
H 指数:15论文数:96被引数:1,134
H
Hideharu Kimura
H 指数:29论文数:187被引数:3,502
T
Toshihiro Misumi
H 指数:20论文数:323被引数:2,466
S
Shigeru Tanzawa
H 指数:9论文数:48被引数:210
H
Hayato Koba
H 指数:11论文数:91被引数:776